癌症治疗中的NFE2L2和铁灭性耐药性
1Department of Surgery, University of Texas Southwestern Medical Center, Dallas, TA 75390, USA.
Cancer drug resistance (Alhambra, Calif.)
|November 13, 2024
概括
类似NFE2的基本氨酸拉链转录因子2 (NFE2L2) 保护正常细胞,但通过抑制铁亡,促进癌症药物耐药性. 准NFE2L2可能会增强基于铁亡的癌症疗法.
科学领域:
- 在瘤学瘤学.
- 细胞死亡机制 细胞死亡机制
- 分子生物学分子生物学
背景情况:
- NFE2L2 (NRF2) 是一种转录因子,对细胞防御氧化应激至关重要.
- 它在癌细胞存活和治疗耐药性方面的作用已得到充分证实.
- 铁亡是一种依赖于铁的调节细胞死亡形式,涉及脂质过氧化.
研究的目的:
- 审查NFE2L2和癌细胞中的铁亡之间的复杂关系.
- 阐明NFE2L2如何影响癌细胞对铁亡的抵抗力.
- 探索针对NFE2L2的治疗策略,以增强ferroptosis诱导.
主要方法:
- 对调查NFE2L2和铁亡的研究进行文献综述.
- 对将NFE2L2与ferroptosis调节联系起来的分子通路的分析.
- 确定关键的NFE2L2点基因参与铁灭菌耐药性.
主要成果:
- NFE2L2激活保护正常细胞免受氧化损伤.
- 癌细胞中的NFE2L2过度表达通过调节抗氧化防御来促进药物耐药性.
- 通过各种向基因,NFE2L2 通过癌细胞中的铁灭活性抑制.
结论:
- NFE2L2具有双重作用,在正常细胞中提供保护,但在癌症中促进药物耐药性.
- 了解NFE2L2对ferroptosis的调节是开发新的癌症治疗方法的关键.
- 准NFE2L2可以使癌细胞对铁灭诱导剂敏感,从而改善治疗结果.
更多相关视频
相关概念视频
Necrosis
4.3K
Necrosis is considered as an “accidental” or unexpected form of cell death that ends in cell lysis. The first noticeable mention of “necrosis” was in 1859 when Rudolf Virchow used this term to describe advanced tissue breakdown in his compilation titled “Cell Pathology”.
Morphological Manifestations of Necrosis
Necrotic cells show different types of morphological appearance depending on the type of tissue and infection. In coagulative necrosis, cells become...
Morphological Manifestations of Necrosis
Necrotic cells show different types of morphological appearance depending on the type of tissue and infection. In coagulative necrosis, cells become...
4.3K
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Electron Transport Chain: Complex I and II
11.9K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
11.9K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Drugs that Stabilize Microtubules
2.0K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.0K
Cancer Therapies
7.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K


